Aethlon Medical stockholders approve share plan increase and other proposals at annual meeting

Aethlon Medical, Inc. held its Annual Meeting of Stockholders on October 1, 2026 in a virtual format, according to an 8-K filed with the Securities and Exchange Commission. As of the August 10, 2026 record date, 711,136 shares of common stock were issued and outstanding.¹ A quorum was present, with 399,752 shares, or approximately 56.21%, represented by proxy or in person.¹

Stockholders elected five directors: Edward G. Broenniman, James B. Frakes, Nicolas Gikakis, Angela Rossetti, and Chetan S. Shah, MD, each to serve until the next annual meeting. Stockholders also ratified Haskell & White LLP to serve as the company's outside auditor for the fiscal year that will end March 31, 2027.¹

Stockholders approved the issuance of up to 1,126,602 shares of common stock issuable upon exercise of Common Warrants and Placement Agent Warrants from the company's July 2026 offering, as required under Nasdaq Listing Rule 5635(d).¹ They also approved, on an advisory basis, the compensation of the company's named executive officers.

Stockholders approved an amendment to the 2020 Equity Incentive Plan to increase the shares authorized for issuance under the plan by 100,000 shares, a change the board had already approved on July 10, 2026, subject to stockholder approval.¹ This amendment took effect on October 1, 2026 once stockholder approval was obtained.¹

Stockholders approved raising the company's authorized common stock from 20,000,000 to 200,000,000 shares.¹ They also authorized 20,000,000 shares of preferred stock, giving the board power to set the terms of future series.¹ Additional proposals covering future private financings and warrant exercise inducement transactions under Nasdaq Rule 5635(d) were approved as well. A tenth proposal allowing adjournment of the meeting to solicit more proxies also passed, but the meeting's chairman chose not to adjourn.¹